Accolade (NASDAQ:ACCD) Announces Quarterly Earnings Results

Accolade (NASDAQ:ACCD - Get Free Report) issued its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01, Briefing.com reports. The company had revenue of $124.80 million during the quarter, compared to analyst estimates of $123.91 million. Accolade had a negative return on equity of 27.27% and a negative net margin of 31.59%. The firm's quarterly revenue was up 26.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.42) EPS. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Price Performance

ACCD stock traded down $1.30 during trading on Friday, hitting $7.89. The stock had a trading volume of 1,491,173 shares, compared to its average volume of 728,244. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.35 and a quick ratio of 2.35. Accolade has a twelve month low of $6.33 and a twelve month high of $17.00. The stock has a market capitalization of $610.76 million, a P/E ratio of -4.81 and a beta of 2.08. The company's 50-day moving average price is $9.75 and its two-hundred day moving average price is $9.92.

Analysts Set New Price Targets

Several brokerages have weighed in on ACCD. Barclays cut their price target on Accolade from $13.00 to $11.00 and set an "equal weight" rating on the stock in a research report on Friday. Canaccord Genuity Group cut their price target on Accolade from $18.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday. Piper Sandler increased their price target on Accolade from $12.00 to $15.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 9th. Morgan Stanley cut their price target on Accolade from $13.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Friday. Finally, Needham & Company LLC dropped their target price on Accolade from $17.00 to $13.00 and set a "buy" rating on the stock in a research report on Friday. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, Accolade has an average rating of "Moderate Buy" and an average target price of $14.80.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.